Rocket Lab’s Stock Momentum Continues Unabated in 2026

Rocket Lab USA’s shares are maintaining their remarkable ascent well into 2026, fueled by a landmark defense contract that solidifies the company’s standing as a major player in the national security arena. However, this institutional enthusiasm is being met with significant insider selling, presenting a complex picture for investors.

A Billion-Dollar Catalyst from the U.S. Space Force

The primary driver behind the stock’s powerful rally is a historic, single-award contract from the U.S. Space Development Agency, secured in December. This agreement represents the largest in Rocket Lab’s history, with a base value of $806 million and the potential to expand to approximately $1 billion through additional options.

The contract covers the design and manufacture of 18 satellites for missile defense systems, plus related services. Market observers interpret this deal as definitive proof of the company’s evolution beyond a mere launch provider for small payloads, marking its establishment as a trusted partner for critical defense infrastructure. This milestone follows an impeccable operational record in 2025, where Rocket Lab achieved a 100% launch success rate across 21 Electron missions.

Financial Performance and Lofty Valuation

Operationally, the company remains on a strong growth trajectory, reporting a 48% year-over-year revenue increase for the third quarter of 2025. This performance is bolstered by additional agreements with space agencies, including the Canadian Space Agency (CSA) and the Japan Aerospace Exploration Agency (JAXA).

Nevertheless, the current valuation demands scrutiny. Based on forward projections for the 2027 fiscal year, the stock trades at a price-to-sales (P/S) ratio of about 34. This premium multiple forces investors to consider whether the company’s aggressive growth strategy can justify such a high valuation over the long term.

Should investors sell immediately? Or is it worth buying Rocket Lab USA?

Analysts Rush to Adjust Targets

The confluence of operational excellence and new contract wins has compelled Wall Street analysts to revise their outlooks upward. Needham dramatically raised its price target from $63 to $90, while Stifel increased its target to $85 per share.

Rocket Lab’s stock closed at $84.85 on Friday, representing a staggering gain of over 211% in the past twelve months alone. This surge has already outpaced many consensus estimates; the average analyst price target now sits at $61.25, significantly below the current trading level.

Insider Sales Cast a Shadow of Caution

Amid the euphoria surrounding government contracts, a contrasting trend has emerged from the company’s leadership. While institutional investors like Invesco have increased their holdings, corporate insiders have been offloading shares on a substantial scale.

Over the past 90 days, insiders have sold approximately $262.4 million worth of stock. This includes Chief Commercial Officer Frank Klein, who divested shares valued at roughly $7.3 million in early January. This activity serves as a notable counterpoint to the bullish institutional sentiment, suggesting that those with the closest view of the company’s prospects are capitalizing on the elevated share price.